Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 209, Issue 4, Pages 679-696Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20111512
Keywords
-
Categories
Funding
- NCI [2T32CA108462, 1K23CA121994, 1K08CA104032, 1R01CA136717]
- Howard Hughes Medical Institute
- UC Cancer Coordinating Committee
- AHA [SDG3420042]
- Susan G. Komen Foundation
- UCSF SPORE [5P50CA058207]
- V-Foundation
- I-SPY
- NCI SPORE [CA58207]
- ACRIN [U01 CA079778, CA080098]
- CALGB [CA31964, CA3360]
Ask authors/readers for more resources
Estrogen, progesterone, and HER2 receptor-negative triple-negative breast cancers encompass the most clinically challenging subtype for which targeted therapeutics are lacking. We find that triple-negative tumors exhibit elevated MYC expression, as well as altered expression of MYC regulatory genes, resulting in increased activity of the MYC pathway. In primary breast tumors, MYC signaling did not predict response to neoadjuvant chemotherapy but was associated with poor prognosis. We exploit the increased MYC expression found in triple-negative breast cancers by using a synthetic-lethal approach dependent on cyclin-dependent kinase (CDK) inhibition. CDK inhibition effectively induced tumor regression in triple-negative tumor xenografts. The proapoptotic BCL-2 family member BIM is up-regulated after CDK inhibition and contributes to this synthetic-lethal mechanism. These results indicate that aggressive breast tumors with elevated MYC are uniquely sensitive to CDK inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available